文献速递胸部肿瘤放疗放疗物理与技术

超中央型肺癌SBRT的剂量学结果:SUNSET试验启示

Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-03

分析未发现OAR剂量与毒性相关,PTV与OAR重叠体积增大与局部控制下降相关,而PTV覆盖不足与总生存降低相关。

要点

  • OAR剂量(D1 cm³和D0.1 cm³)与≥2级毒性无关联

核心结论

  • 在试验采用的剂量约束范围内,未发现OAR剂量与毒性之间的关系。
  • 局部控制随PTV与OAR重叠增加而下降,但这与靶区剂量覆盖不足无关。

主要发现

  • 中位随访36.5个月,11例发生≥2级毒性。
  • PTV与58个中央OAR重叠,最常见为气道(n=26)。
  • PTV D98均值±SD为56.1±7.8 Gy,近端支气管树、食管和肺动脉D0.1 cm³分别为53.1±12.6 Gy、26.5±10.5 Gy和57.0±8.6 Gy。

关键数值与推荐

  • 处方剂量60 Gy/8次,最大剂量限制为处方剂量的120%。
  • OAR剂量(D1 cm³和D0.1 cm³)与毒性无关联。

临床怎么用

  • 在超中央型肺癌SBRT中,应关注PTV与OAR的重叠体积对局部控制的影响。
  • 靶区覆盖不足可能与总生存下降相关,需权衡覆盖与OAR约束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Stereotactic Radiation Therapy for Ultra-Central Non-Small Cell Lung Cancer: Safety and Efficacy Trial (SUNSET) trial investigated the maximum tolerated dose for ultracentral lung tumors treated with stereotactic body radiation therapy. Here, we report a spatial and dosimetric secondary analysis of the treatment plans and assess relationships between doses to targets, organs at risk (OARs), and clinical outcomes. METHODS AND MATERIALS: Five institutions enrolled patients with ultracentral lung cancer, cT1-3N0M0, and all received 60 Gy in 8 fractions. Maximum dose was limited to 120% of prescription. Planning data sets and treatment plans were imported into a central repository. Univariable logistic and Cox proportional hazards regression modeling were performed to identify significant dosimetric predictors for related grade ≥2 adverse events, overall survival, and local control (LC). RESULTS: Thirty patients were included in this analysis. At median follow-up of 36.5 months, 11 patients experienced grade ≥2 toxicity. The planning target volume (PTV) overlapped with 58 central OARs of which airway was most common (n = 26). The mean maximum dose was 69.3 Gy (range, 63.8-72.0 Gy); all were within the internal target volume. Mean ± SD PTV D98 was 56.1 ± 7.8 Gy, whereas D0.1 cm3 of proximal bronchial tree, esophagus, and pulmonary artery were 53.1 ± 12.6 Gy, 26.5 ± 10.5 Gy, and 57.0 ± 8.6 Gy, respectively. On regression analysis, the combined overlap volume (cm3) of the 2 primary overlapping OARs with PTV was associated with inferior LC (hazard ratio [HR], 2.86; P = .012); however, it was not associated with increase in grade ≥2 adverse events (odds ratio, 1.17; P = .49). There was no association between OAR doses (D1 cm3 and D0.1 cm3) with toxicity. PTV undercoverage (D98) was not associated with worse LC (HR per 5 Gy, 1.54; P = .68); however, lower PTV coverage was significantly associated with reduced overall survival for D98 (HR, 0.65; P = .014) and D95 (HR per 5 Gy, 0.66; P = .035). CONCLUSIONS: Within the dose constraints used in the trial, there was no relationship identified between OAR doses and toxicity. LC decreased with increasing overlap of PTV with OARs; however, this was not associated with dosimetric undercoverage of the target.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Salunkhe R, Palma DA, Warner A, et al. Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40912509. doi:10.1016/j.ijrobp.2025.08.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。